View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
August 16, 2021updated 11 Jul 2022 9:50am

Significant increase in virtual trial deals since 2020 as a result of Covid-19

In line with the increased demand for virtual trial services during the COVID-19 pandemic, many leading clinical research organizations (CROs) and eClinical software providers have expanded their capabilities in this area.

By GlobalData Healthcare

In line with the increased demand for virtual trial services during the COVID-19 pandemic, many leading clinical research organizations (CROs) and eClinical software providers have expanded their capabilities in this area. Several specialist virtual trial providers, such as Medable , Science 37 , and THREAD, have also attracted considerable attention during the pandemic. As a result, there has been a significant increase in all deal-making activity in the virtual trials space over the past 18 months (Figure 1).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

There were nine mergers and acquisitions (M&As) related to virtual trials in 2020, compared to just one in 2018 and two in 2019. In 2021, six M&As have already occurred in this space to date. Examples include Thermo Fisher’s acquisition of Pharmaceutical Product Development (PPD ) for $17.4B in April 2021 and ICON’s acquisition of PRA Health Sciences for $12B in February 2021. Several companies also completed acquisitions of other companies to expand their virtual trial capabilities, including Syneos Health, Signant Health, Covance, and ERT. For example, ERT acquired wearable company APDM in July 2020 and merged with Bioclinica in December 2020 for its clinical trial endpoint technology expertise.

The number of strategic partnerships in the virtual trials space also increased from a quarterly average of three partnerships before the pandemic to a quarterly average of 11 partnerships from Q2 2020–Q1 2021. In Q1 2021 alone, 18 partnerships were identified. Most of these involved specialist virtual trial vendors forging collaborations with CROs, eClinical solution providers, or pharma companies. For example, Science 37 has entered into the most partnerships (13),

with six partnerships in 2020 and four for 2021 to date. THREAD has forged six partnerships since 2020, while both Medable and ObvioHealth entered into five partnerships. The number of VC funding deals also increased from six deals in 2018 to 18 deals in 2020. Most VC funding deal activity was seen in Q3 2020, with 10 deals. Specialist virtual trial vendors and eClinical solution providers have been involved in the most funding rounds. For example, Medable has raised $194M from three rounds since 2020, the most recent being a $78M Series C in April 2021.

While the shift to virtual trials was underway before the pandemic, COVID-19 lockdowns and social distancing measures caused significant disruptions to clinical trials and accelerated the use of virtual trials. Companies that had not considered the virtual trial model before had no option but to rapidly implement new technologies and procedures to maintain business continuity.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology